Ovarian Hyperstimulation Syndrome (OHSS) is a potentially serious complication of assisted reproductive technology (ART). It is caused by an exaggerated response to the hormones used to stimulate ovulation during fertility treatments. OHSS can cause a wide range of symptoms, including abdominal pain, nausea, vomiting, and rapid weight gain. In severe cases, OHSS can lead to serious complications, including dehydration, thromboembolism, and even death. As such, it is important for doctors to be aware of the risk factors for OHSS, as well as strategies for prevention and management. This article provides an overview of OHSS, including risk factors, prevention strategies, and management options.
OHSS is a condition that occurs when the ovaries become overly stimulated in response to fertility medications. The ovaries become enlarged and produce an excessive amount of fluid, which can cause abdominal pain and distention. In some cases, the fluid can accumulate in the chest or abdomen, leading to further symptoms such as shortness of breath, nausea, and vomiting. OHSS can range from mild to severe, with the most severe cases requiring hospitalization.
There are several risk factors for OHSS. The most important factor is the type of fertility medication used. Medications that contain human chorionic gonadotropin (hCG) are more likely to cause OHSS than other types of fertility medications. Additionally, certain patient characteristics can increase the risk of OHSS, including age, body mass index (BMI), and ovarian reserve. Women with a higher BMI or lower ovarian reserve are more likely to experience OHSS.
There are several strategies that doctors can use to reduce the risk of OHSS. First, it is important to identify patients at high risk of OHSS before treatment begins. This can be done by assessing patient characteristics such as age, BMI, and ovarian reserve. Second, lower doses of hCG can be used for patients at high risk of OHSS. Third, doctors can use other fertility medications, such as clomiphene citrate, instead of hCG. Finally, doctors can use monitoring techniques such as ultrasound and blood tests to monitor the response to fertility medications and adjust the dose accordingly.
If OHSS does occur, it is important to take measures to manage the condition. Mild cases of OHSS can usually be managed at home with bed rest, fluids, and pain medication. In more severe cases, hospitalization may be necessary. In the hospital, patients may receive intravenous (IV) fluids, diuretics, and blood transfusions. In addition, doctors may recommend canceling the cycle of fertility treatment or freezing any embryos for transfer at a later date.
OHSS is a potentially serious complication of fertility treatments. as well as strategies for prevention and management. By taking steps to identify patients at high risk of OHSS and using appropriate monitoring techniques, doctors can reduce the risk of OHSS and ensure that appropriate management strategies are in place if the condition does occur.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation